Drug interactions
Dantrolene + Rucaparib
Severity: Minor
Dantrolene and Rucaparib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rucaparib is a weak-to-moderate inhibitor of CYP3A4 and may modestly raise dantrolene concentrations. Because dantrolene carries a risk of dose-related hepatotoxicity, higher exposure could matter during prolonged therapy.
What this interaction means in plain words
Dantrolene and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dantrolene belongs to Musculoskeletal; Rucaparib belongs to Oncology.
Why it happens
Inhibition of CYP3A4 by rucaparib may reduce metabolic clearance of dantrolene, though dantrolene is mainly metabolised by hepatic oxidation and reduction pathways.
What to do
No empirical dose change is needed in most cases. Monitor liver function tests and signs of excessive weakness or sedation during long-term coadministration.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dantrolene and Rucaparib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Dantrolene
Other interactions of Rucaparib
- Cisapride + Rucaparib Major
- Ergotamine + Rucaparib Major
- Pimozide + Rucaparib Major
- Alfuzosin + Rucaparib Moderate
- Aripiprazole + Rucaparib Moderate
- Atorvastatin + Rucaparib Moderate
Frequently asked questions
Can I take Dantrolene with Rucaparib?
MediHelp rates the interaction as minor. Dantrolene and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rucaparib is a weak-to-moderate inhibitor of CYP3A4 and may modestly raise dantrolene concentrations. Because dantrolene carries a risk of dose-related hepatotoxicity, higher exposure could matter during prolonged therapy.
How serious is the interaction between Dantrolene and Rucaparib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose change is needed in most cases. Monitor liver function tests and signs of excessive weakness or sedation during long-term coadministration.
What other medicines interact with Dantrolene?
MediHelp also lists interactions of Dantrolene with, for example, Benzhydrocodone / acetaminophen, Buprenorphine long-acting, Buprenorphine subdermal implant. The full list is on the Dantrolene page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
